Developments in antiviral drug design, discovery and development in 2004

Curr Drug Targets Infect Disord. 2005 Dec;5(4):307-400. doi: 10.2174/156800505774912893.

Abstract

This article summarizes key aspects of progress made during 2004 toward the design, discovery and development of antiviral agents for clinical use. Important developments in the identification, characterization and clinical utility of inhibitors of human immunodeficiency virus; the hepatitis viruses, hepatitis B, hepatitis C; the herpes family of viruses, herpes simplex viruses 1 and 2, varicella zoster virus, Epstein-Barr virus and human cytomegalovirus; the respiratory viruses, influenza, respiratory syncytial virus, human metapneumovirus, picornaviruses, measles and the severe acute respiratory syndrome coronavirus; human papilloma virus; rotavirus; Ebola virus and West Nile virus, are reviewed.

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacology
  • Antiviral Agents / chemistry*
  • Antiviral Agents / pharmacology*
  • Clinical Trials as Topic
  • Drug Design*
  • Drug Evaluation, Preclinical
  • HIV Integrase Inhibitors / chemistry
  • HIV Integrase Inhibitors / pharmacology
  • HIV-1 / drug effects*
  • HIV-2 / drug effects*
  • Hepatitis Viruses / drug effects*
  • Herpesviridae / drug effects*
  • Humans
  • Molecular Sequence Data
  • Molecular Structure
  • Nucleic Acid Synthesis Inhibitors
  • Nucleosides / chemistry
  • Nucleosides / pharmacology
  • Orthomyxoviridae / drug effects
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / chemistry
  • Reverse Transcriptase Inhibitors / pharmacology
  • Severe acute respiratory syndrome-related coronavirus / drug effects

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • HIV Integrase Inhibitors
  • Nucleic Acid Synthesis Inhibitors
  • Nucleosides
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors